Journal of cancer research and therapeutics最新文献

{"title":"Pleomorphic adenoma: Indeed, a versatile tumor.","authors":"Rashim Sharma, Sudeep Khera, Taruna Yadav, Mayank Badkur","doi":"10.4103/jcrt.jcrt_2259_22","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_2259_22","url":null,"abstract":"<p><strong>Abstract: </strong>Pleomorphic adenoma is the most common and well-studied salivary gland neoplasm. It is a benign tumor most commonly occurring in the parotid gland although it can be seen in other major and minor salivary glands. There is a variety of metaplasia seen in Pleomorphic adenoma most commonly squamous metaplasia, others noted are osseous metaplasia, oncocytic metaplasia, sebaceous metaplasia, and adipocytic metaplasia. Also, at times tyrosine crystalloids are seen. This study discusses a few of the metaplasia and the presence of tyrosine crystals in pleomorphic adenoma. Indeed, this tumor proves true to its name.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"20 5","pages":"1611-1614"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression of stem cell biomarker CD44 in oral squamous cell carcinoma and its association with lymph node metastasis and TNM staging.","authors":"Satadruti Chakraborty, T N Suresh, S M Azeem Mohiyuddin","doi":"10.4103/jcrt.jcrt_178_23","DOIUrl":"10.4103/jcrt.jcrt_178_23","url":null,"abstract":"<p><strong>Background: </strong>Oral squamous cell carcinoma (OSCC) is one of the most prevalent cancers in the world. OSCC is a highly invasive lesion frequently having soaring morbidity as well as substantial mortality, attributed to resistance to therapy, metastasis, and recurrence driven by specific populations of cancer stem cells (CSC). The evidence of the association of expression of stem cell biomarker CD44 and metastatic potential of the tumor is inconclusive in OSCC and hence needs further evaluation.</p><p><strong>Objectives: </strong>To determine the immunohistochemical expression of CD44 in OSCC and to find its association with lymph node metastasis and TNM staging.</p><p><strong>Materials and methods: </strong>One hundred and five histologically proven cases of OSCC were studied. Histopathological parameters like depth of invasion, presence of lymph node metastasis, grading, and TNM staging were done according to the new AJCC staging criteria. Both intensity and proportion of CD44 expression were recorded.</p><p><strong>Results: </strong>The mean age observed in this study was 52.59 years with a male: female ratio of 1:3.76. Forty-nine cases (46.6%) showed a depth of invasion of more than 10 mm. Fifty-two out of one hundred and five cases (49%) had nodal involvement. TNM staging was 5.7%, 7.6%, 44.7%, and 42% for stages I, II, III, and IV, respectively. The majority of the cases (87.5%) showed CD44 expression in the tumor. There was a significant association between the CD44 expression and lymph node metastases (P < 0.001). Higher CD44 expression was seen in stages III and IV (P < 0.001).</p><p><strong>Conclusion: </strong>CD44, a stem cell biomarker is significantly associated with higher TNM stage and lymph node metastases. This may be useful in predicting the tumor behavior in the small biopsy.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"20 5","pages":"1430-1434"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of an anticancer activity of combination of interferon-alpha and gemcitabine on pancreatic cancer cells.","authors":"Orkhan Isayev, Darina V Sokolova, Natalia Yu Anisimova, Tatiana S Spirina, Eldar Gasimov","doi":"10.4103/jcrt.jcrt_138_23","DOIUrl":"10.4103/jcrt.jcrt_138_23","url":null,"abstract":"<p><strong>Abstract: </strong>Pancreatic ductal adenocarcinoma (PDAC) is still a clinical challenge due to its deteriorated prognosis. Therefore, new combination chemotherapeutic approaches are of research interest. In this work, we attempted to characterize the effects of gemcitabine and interferon-alpha as well as the combination of both on the metabolic, pro-apoptotic, and proliferative activity of MiaPaca and Panc-1 cells. We showed that the exposure of both drugs in combination increases effectively the metabolic activity of cells of MiaPaca and Panc-1 cell lines compared to the monotherapies. Based on the data from the analysis of apoptosis, the underlying molecular effect of metabolic and proliferative inhibition is an increase in the number of cells in the early apoptosis. These data can be of interest in the context of future preclinical research.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"20 5","pages":"1494-1498"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SALL4 and C-kit positive malignant extrarenal rhabdoid tumor of the pelvis in a child: A diagnostic and therapeutic challenge.","authors":"Saloni Pahwa, Sunil Pasricha, Gauri Kapoor, Ankush Jajodia, Venkata Pradeep Babu Koyyala, Anurag Mehta","doi":"10.4103/jcrt.jcrt_2203_22","DOIUrl":"10.4103/jcrt.jcrt_2203_22","url":null,"abstract":"<p><strong>Abstract: </strong>Extrarenal rhabdoid tumors (ERRTs) are highly aggressive pediatric tumors with very few cases reported in the literature. These tumors, similar to their renal counterparts, are characterized by inactivating mutations of the SMARCB1/INI-1 gene, a member of the SWI/SNF chromatin remodeling pathway. Diagnosis of ERRTs appears challenging owing to its rarity, varied morphological profile with a higher tendency for rhabdoid differentiation, and overlapping features with other SMARCB-1 deficient tumors. Here, we report a case of ERRT in the pelvis of a three-year-old child with an unusual expression of SALL4 and C-kit on immunohistochemistry. A complete immunohistochemical workup might help in differentiating ERRTs from other SMARCB1/INI1-deficient soft tissue tumors. The expression of stem cell markers in the presented case also suggests that these tumors might originate from or share similarities with embryonic stem cells or germ cells.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"20 5","pages":"1618-1621"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of gross target volumes in CECT vs MRI in head and neck cancer and its implication on concordance indices and dose-volume parameters of IMRT treatment plan.","authors":"Milind Deshmukh, Bharati M Jain, Ashok Singh, Pallavi Kalbande, Atul Tayade, Niloy R Datta","doi":"10.4103/jcrt.jcrt_246_23","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_246_23","url":null,"abstract":"<p><strong>Background: </strong>Although radiotherapy treatment planning (RTP) for head and neck cancers (HNCs) is based on contrast enhanced computed tomography (CECT), soft tissue contrasts are better evident on magnetic resonance imaging (MRI). We therefore evaluated dose-volume histogram (DVH) parameters along with concordance index (ConI), conformity index (CI), and homogeneity index (HI) of planning target volume (PTV) of GTV delineated on CECT vs MRI in HNCs enrolled for intensity modulated radiotherapy (IMRT).</p><p><strong>Methodology: </strong>Forty consecutive HNCs were enrolled in this study. All underwent CECT and MRI simulations with immobilization devices. GTVp and GTVn were delineated independently on CECT and MRI images. Corresponding MRI volumes were then copied to CECT. IMRT plans were generated on the CECT incorporating PTV margins. DVH parameters of PTVpn for both CECT and MRI were compared. In addition, mean (±SD) percentage difference of GTVp, GTVn, GTVpn, ConI, CI, and HI were evaluated using paired t-test.</p><p><strong>Results: </strong>The GTVp (P = 0.005), GTVn (P = 0.009), and GTVpn (P < 0.001) delineated on MRI were found to be significantly larger than GTV delineated on CECT. In eight patients, GTV outlined on CECT were larger than MRI. Significant mean differences in CECT vs MRI of CI (P < 0.001), HI (P < 0.001), ConI (P < 0.001), and DVH parameters (D2, D95, D98, V95, and V100 all P < 0.001; D50: P = 0.009) were noted.</p><p><strong>Conclusion: </strong>The GTVs and corresponding PTVs were significantly larger on MRI compared to CECT. This resulted in significant differences in DVH parameters, CI, ConI, and HI. This could be improved by co-registered MRI-CECT volumes during routine IMRT treatment planning for HNCs.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"20 5","pages":"1533-1538"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Receptor subtype and outcome of breast cancer - Single-center experience from North India.","authors":"Saquib Z Banday, Maniza Ayub, Malik T Rasool, Sheikh Z Ahmed, Aaqib Z Banday, Shah Naveed, Faisal R Guru, Mohmad H Mir, Shareefa Akhter, Mudasir H Bhat, Syed B Yaseen, Fir Afroz, Gull M Bhat, Mohammad M Lone, Shiekh A Aziz","doi":"10.4103/jcrt.jcrt_56_23","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_56_23","url":null,"abstract":"<p><strong>Aims/objectives: </strong>In resource-limited settings, data regarding the impact of molecular/receptor subtypes on breast cancer (BC) are sparse. In this single-center retrospective study from north India, we analyze the outcomes of various molecular subtypes of BC.</p><p><strong>Materials and methods: </strong>Females with biopsy-proven BC who were treated at our State Cancer Institute from 2014-2018 were included. Data regarding clinicopathological parameters and follow-up details were evaluated. For data analysis, cancers were categorized into 4 subtypes: HR+HER2-, HR+HER2+, HR-HER2+, and HR-HER2-.</p><p><strong>Results: </strong>Among 944 patients included, HR+HER2- (49.1%) and HR+HER2+ (13.1%) were the most and least common subtypes, respectively. The receptor subtype significantly impacted overall survival (OS). HR+HER2- cancers had the best outcomes while HR-HER2- cancers fared worst (3-yr OS of 94.3% and 69.1%, respectively). On subgroup analysis, the molecular subtype continued to significantly impact OS in patients with tumor grades II and III, disease stages II and III, and age groups of <40 and 40-60 years, respectively (HR-HER2- cancers had the lowest cumulative survival in each subgroup). In patients with metastatic BC, all molecular subtypes except HR+HER2- had a dismal prognosis.</p><p><strong>Conclusions: </strong>Overall and across various subgroups, patients with triple-negative BC had the poorest outcomes. Ensuring optimal treatment utilization including affordable access to personalized tailored therapy is the need of the hour to improve long-term outcomes in these patients.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"20 5","pages":"1486-1493"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of quality of voice after 3D conformal hypofractionated radical radiotherapy in early-stage glottic cancer: A prospective study.","authors":"Shalini Singh, Viney Kumar, Vipul Nautiyal, Meenu Gupta, Saurabh Bansal, Mushtaq Ahmad","doi":"10.4103/jcrt.jcrt_1540_22","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_1540_22","url":null,"abstract":"<p><strong>Purpose: </strong>The purpose of this study was to evaluate the short-term outcomes in terms of oncological outcomes, toxicities, and impact of quality of voice on livability of early glottic cancer (EGC) (T1) patients after hypofractionated radiotherapy.</p><p><strong>Material and methods: </strong>30 patients of early glottic carcinoma, staged cT1a-T1bN0M0 with Eastern Cooperative Oncology Performance Status (ECOG PS ≤ 2). Exclusion criteria included ECOG PS > 2, T2-T4 disease, and any other head and neck malignancy. Voice Handicap Index-10 (VHI-10) was used to score voice outcomes of patient's pre- and post-radiation.</p><p><strong>Results: </strong>All the subjects were predominantly smokers (80%) having hoarseness of voice as the most common presenting complaint (76.7%) followed by dry cough (13.3%) and foreign body sensation (10%). On posttreatment response assessment, there has been a significant reduction in VHI-10 scores from pre-radiotherapy (RT) to 6, 12, and 24 weeks post-radiation completion in all three domains (functional, emotional, and physical), as well as total scores, with a significant P value (<0.05) being observed.</p><p><strong>Conclusion: </strong>The use of modest hypofractionated regimen (63 Gy in 28 fractions) in patients of early glottic disease (T1a and T1b) posttreatment completion provides good oncological outcomes with better quality of voice being observed.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"20 5","pages":"1512-1516"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comparative study between two different dose fractionation schedules of cobalt-60-based HDR intracavitary brachytherapy in carcinoma cervix stages IIB-IIIC1.","authors":"Vaibhav Gagrani, Jyoti Kabara, Arvind Shukla, N K Rathore, Vikram S Rajpurohit, Pawan K Jangid, Sumanta Manna","doi":"10.4103/jcrt.jcrt_286_23","DOIUrl":"10.4103/jcrt.jcrt_286_23","url":null,"abstract":"<p><strong>Introduction: </strong>High dose rate (HDR) intracavitary brachytherapy (ICBT) is an integral element in the treatment of carcinoma uterine cervix. The main objective of brachytherapy in carcinoma cervix is to deliver a lethal dose to tumor cells without inducing unacceptable damage to the surrounding normal tissue. Because the absorbed dose falls off rapidly, higher doses can be safely delivered to the targeted tissue over a short time. The quest for optimum dose and fractionation schedule in HDR ICBT is still ongoing, and there is no uniform consensus. This study aimed to assess the acute dose-related toxicities of HDR brachytherapy schedule of 7 Gy x 3 fractions over 6 Gy x 4 fractions in the treatment of cervical cancer.</p><p><strong>Objective: </strong>The aim of this study was to study the acute treatment-related gastrointestinal (GI) and genitourinary (GU) toxicities between two HDR brachytherapy regimens.</p><p><strong>Material and methods: </strong>This is a prospective institutional study carried out from May 2018 to September 2018. In this time period, 66 patients of cervical cancers fulfilling our inclusion criteria were treated with concurrent chemoradiation (CCRT) following brachytherapy. During treatment, patients were randomized to arm A-7 Gy per fraction for three fractions and arm B-6 Gy per fraction for four fractions. Acute GI and GU toxicities were assessed using Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. All patients were kept for follow-up for 3 months in this study.</p><p><strong>Results: </strong>There is no statistically significant difference between the two arms for acute GI and GU toxicities, and the results were comparable.</p><p><strong>Conclusions: </strong>Considering the increased hospital burden of locally advanced cervical cancer patients in the Indian context, the HDR brachytherapy schedule of 7 Gy per fraction is preferable to 6 Gy per fraction for a lesser fractionation schedule.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":" ","pages":"1551-1556"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139543611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary vaginal squamous cell carcinoma-the coeffect of vaginal leiomyoma and Human papillomavirus (HPV); A case report.","authors":"Hanife S Mavili, Ali R Kandiloğlu, Ömer Atmış, Yıldız Uyar","doi":"10.4103/jcrt.jcrt_2108_22","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_2108_22","url":null,"abstract":"<p><strong>Abstract: </strong>Primary vaginal squamous cell carcinoma (SCC) is extremely rare. Primer vaginal SSC developed by the coeffect of leiomyoma and Human papillomavirus (HPV) is presented. We report a case of primary vaginal SCC in a 62-year-old woman presenting dyspareunia. On macroscopic examination, the surface of the operation material was partly ulcerated. On the cut surface, the material was solid, firm, white, and whorled. Microscopic examination revealed leiomyoma ulcerating the mucosa and SCC at the base of the ulcer. The case, in which vaginal SCC developed in the vagina due to the irritation of the leiomyoma, as well as its relationship with HPV, is important to be the first to our knowledge.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"20 5","pages":"1622-1624"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"Evaluation of the efficacy of adjuvant radiotherapy versus chemoradiotherapy in patients with salivary gland tumors\".","authors":"Erkan Topkan, Efsun Somay","doi":"10.4103/jcrt.jcrt_216_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_216_24","url":null,"abstract":"","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"20 5","pages":"1662-1663"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}